BioBalance has received a U.S. patent for its inflammatory bowel disease treatment Probactrix, the company said.
BioBalance received the patent March 28 for Probactrix, a strain of E.coli. Inflammatory bowel disease includes Crohn's disease and ulcerative colitis, which together affect 1 million Americans, BioBalance said.